Ozempic for All?

Ozempic for All?

0 Anmeldelser
0
Episode
2548 of 2687
Længde
24M
Sprog
Engelsk
Format
Kategori
Fakta

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.

Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.

Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.

Background reading:

• How Ozempic’s maker lost its shine • after creating a wonder drug. What Trump’s new drug pricing deal means • for people with obesity.

Photo: Sergei Gapon/Agence France-Presse — Getty Images

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.


Lyt når som helst, hvor som helst

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

  • Lyt og læs så meget du har lyst til
  • Opdag et kæmpe bibliotek fyldt med fortællinger
  • Eksklusive titler + Mofibo Originals
  • Opsig når som helst
Prøv nu
DK - Details page - Device banner - 894x1036
Cover for Ozempic for All?

Other podcasts you might like ...